ClinicalTrials.gg
Active, not recruitingNCT01909245TCDUpdated Oct 26, 2026

Islet Cell Transplant for Type 1 Diabetes

A Phase 2 interventional study of Allogenic Human Islet Cells and Immunosuppressive Agents in Type 1 Diabetes Mellitus, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 68 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 26, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 68 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 53 studies testing Immunosuppressive Agents in Diabetes Mellitus, Type 1 — 3 open to participants now, 6 under way, none of them phase 3. A drug class: Immunosuppressive Agents · Diabetes Mellitus, Type 1.

Enrollment
30th of 53
10 · median 14
Started
2015
with 3 others
Phase 2
28 of 53
3 open now
Registered
32nd of 53
by date

Among the 53 studies testing Immunosuppressive Agents in Diabetes Mellitus, Type 1, this one is the 30th largest by enrollment, is one of 4 that started in 2015, is one of 28 in phase 2, and was the 32nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 53 studies testing Immunosuppressive Agents in Diabetes Mellitus, Type 1 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Immunosuppressive Agents

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 68 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing Immunosuppressive Agents in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

City of Hope National Medical Center, located in Duarte, CA, is hosting a clinical study on islet cell transplantation, an experimental procedure being evaluated as a treatment for patients with type 1 diabetes. Islet cell transplantation involves taking insulin-producing cells from organ donors and transplanting them into the liver of a patient with diabetes. Once transplanted, the islets produce insulin, which can improve blood sugar control and eliminate the need to inject insulin or use an insulin pump.

Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that work by decreasing a patient's T-cells. T-cells are special white blood cells that recognize and destroy unwanted things like infections but can also attack transplanted cells and organs. Reducing the number of T-cells at the time of transplant may protect islets and improve long-term transplant success. In previous research studies, islet transplantation has been successful in reducing low blood sugar episodes, improving overall blood sugar control, and in some cases, allowing patients with type 1 diabetes to stop taking insulin.

The purpose of this study is to determine if islet cell transplantation using ATG or alemtuzumab, along with additional medications to prevent the body from rejecting the transplanted cells, is a safe and effective treatment for type 1 diabetes. Study participants may receive up to three islet transplants and will be followed for five years to monitor blood sugar control, islet transplant function, and changes in quality of life.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Islet cells
  • hypoglycemia
  • hypoglycemia unawareness
  • islet after kidney transplantation
  • islet transplant
  • insulin independence
  • insulin dependence
  • labile diabetes
04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Three different categories of patients with Type 1 Diabetes will be considered for study participation:

  • Naïve islet transplant alone (nITA) candidates: T1D patients complicated by frequent/severe hypoglycemia, hypoglycemia unawareness, AND/OR otherwise unstable blood glucose control who have not received a previous transplant (except for a failed pancreas more than 6 months prior to screening)
  • Repeat transplant (RT) candidates: T1D patients who have received two or fewer previous islet transplants > 1 month prior to screening, but continue to require exogenous insulin treatment or have an > 6.5%
  • Islet after kidney transplant (IAK) candidates: T1D patients with a history of successful renal transplant > 3 months prior to screening

Inclusion criteria

Inclusion criteria for all candidates:

  1. Age 18-68 years
  2. Type 1 diabetes mellitus for at least 5 years
  3. Ability and willingness to comply with post-transplant regimen, including taking anti-rejection medications, use of reliable , frequent clinic visits, lab tests, careful recording of blood glucose values, insulin doses and medications, and completing detailed follow-up studies

    Additional Inclusion Criteria nITA Candidates Only

  4. Unstable blood sugar control characterized by:

    Frequent hypoglycemia (blood glucose ≤ 54 mg/dl more than once per week) -AND/OR- Hypoglycemia unawareness (Clarke score of 4 or more) -AND/OR- One or more severe hypoglycemic episodes in 12 months preceding enrollment. -AND/OR- Erratic blood glucose levels that interfere with daily activities -AND/OR- One or more hospital visits for diabetic ketoacidosis in the 12 months preceding enrollment

    Additional Inclusion Criteria for RT Candidates Only

  5. One or two or previous islet transplants > 1 month prior to screening with continuing insulin requirements and/or HbA1c > 6.5%

    Additional Inclusion Criteria for IAK Candidates Only

  6. Successful kidney transplant > 3 months prior to screening
  7. Stable maintenance consisting of tacrolimus alone or in conjunction with sirolimus, mycophenolate mofetil, myfortic or azathoprine; or cyclosporine in conjunction with sirolimus, mycophenolate mofetil, or myfortic +/- ≤ 10 mg/day
  8. No history of acute rejection related to kidney graft in last 12 months and low risk of rejection
  9. Under continuing care of physician for kidney graft, who has provided letter in support of candidate's consideration for study participation

Exclusion criteria

Exclusion Criteria:

  1. (BMI) > 33
  2. Insulin requirements > 1.2 units/kg/day
  3. Known sensitization to both rATG -and- alemtuzumab
  4. Significant kidney dysfunction
  5. Significant liver/gall bladder disease
  6. Significant cardiovascular disease
  7. Active proliferative retinopathy
  8. High blood pressure despite appropriate treatment
  9. High cholesterol/triglycerides despite appropriate treatment
  10. Anemia or other blood disorders that require medical treatment
  11. WBC \<3,000/ul
  12. Increased risk of bleeding, other chronic hemostasis disorders, or treatment with chronic anticoagulant therapy
  13. Recent unresolved acute infection (except for mild skin infection or nail fungal infection), or chronic infection
  14. Epstein-Barr Virus (EBV) IgG negative
  15. Any history of , except for completely resected squamous or basal cell carcinoma of the skin or in situ cancer of the cervix
  16. Recent history of non-adherence to medical treatment, or inability to demonstrate capacity to comply with strict blood glycemic control and insulin therapy
  17. Psychiatric illness that is untreated, or likely to interfere significantly with study compliance despite treatment
  18. Previous organ/tissue transplant, except as noted above
  19. Administration of within 2 months of enrollment
  20. Presence of a chronic disease that must be chronically treated with a agent
  21. Use of agents within four weeks of enrollment
  22. Active alcohol or substance abuse, including cigarette smoking
  23. Pregnant women, women intending future pregnancy, women of who are unable or unwilling to follow effective measures prior to study entry and for as long as they are on medication, and women presently breast feeding are excluded
  24. Individuals without health insurance
  25. History of gastric bypass
  26. Any medical condition that in the opinion of the investigator will interfere with safe participation in the trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Single Arm Study

    Allogenic Human Islet Cell Transplant with immunosuppression

    Biological: Allogenic Human Islet Cells · Drug: Immunosuppressive Agents · Drug: Gastrin 17

Interventions

  • BiologicalAllogenic Human Islet Cells

    Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.

    Also known as: Islet transplant, islet transplantation

  • Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.

  • DrugGastrin 17

    Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).

    Also known as: GAST-17

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < or = 6.5% at 1 year post-transplant

    Time frame: 1 year post-transplant

  2. Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < or = 6.5% at 2 years post-transplant

    Time frame: 2 years post-transplant

  3. Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < or = 6.5% at 5 years post-transplant

    Time frame: 5 years post-transplant

Secondary outcomes

  1. Proportion of subjects who are free of severe hypoglycemic episodes AND have a hemoglobin A1c < or = 7.0%

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

Other outcomes

  1. Proportion of subjects experiencing reduction/elimination of hypoglycemic episodes

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  2. Duration of insulin independence

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  3. Proportion of subjects who maintain a positive c-peptide secretion response to glucose/glucagon stimulation

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  4. Change in average daily insulin use compared to baseline

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  5. Decline in insulin intake/100,000 IEQ infused

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  6. Insulin secretion during Intravenous Glucose Tolerance Test (IVGTT), IVGTT+arginine stimulation (IVGTT+AST), Maximum Stimulated Insulin Secretion test (MSIS), and/or Mixed Meal Tolerance Test (MMTT)

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  7. Rate of alloimmune rejection

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  8. Rate of autoimmune reactivation

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  9. Incidence and severity of adverse events related to islet transplant procedure

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  10. Incidence and severity of adverse events related to immunosuppression

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  11. Incidence of change in immunosuppression drug regimen

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  12. Incidence of immune sensitization defined by presence of anti-HLA antibodies post-transplant that were absent pre-transplant

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  13. Incidence of discontinuation of immunosuppression

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  14. Improvement in glucose time within range during continuous glucose monitoring

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  15. Improvement in Personal Glycemic State (PGS) score calculated from continuous glucose monitoring

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

  16. Incidence of Gastrin-17 use for treatment of islet graft dysfunction AND incidence of change or early discontinuation of Gastrin-17 treatment

    Time frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant

07

Study locations

1 site
08

References and documents

Publications

  • Aslamy A, Oh E, Ahn M, Moin ASM, Chang M, Duncan M, Hacker-Stratton J, El-Shahawy M, Kandeel F, DiMeglio LA, Thurmond DC. Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. J Clin Endocrinol Metab. 2018 May 1;103(5):1966-1976. doi: 10.1210/jc.2017-02492. PubMed 29506054 ↗
  • Orr C, Stratton J, El-Shahawy M, Forouhar E, Peng A, Singh G, Omori K, Qi M, Kandeel F. Impact of Tacrolimus, Sirolimus, Age, and Body Mass Index on the Occurrence of Skin Cancer and Islet Dysfunction After Transplantation. Cell Transplant. 2025 Jan-Dec;34:9636897241309412. doi: 10.1177/09636897241309412. PubMed 39780302 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2015 (actual). Primary completion is estimated for Aug 2027, 145 months after the start.

Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 145 months is above that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Oct 2013 → Jul 2015, primary completion Sep 2026 → Aug 2027 and completion Sep 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2013
First posted
Jul 26, 2013
StartActual
Jul 10, 2015was Oct 2013
Primary completionEst.
Aug 31, 2027was Sep 2026
CompletionEst.
Aug 31, 2027was Sep 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 16, 2013→Jul 10, 2015
Oct 26, 2026
Primary completion
Sep 22, 2026→Aug 31, 2027
Oct 26, 2026
Study completion
Sep 22, 2026→Aug 31, 2027
Oct 26, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39780302 ↗
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39780302 ↗
    Start date Oct 16, 2013→Jul 10, 2015
    Primary completion Sep 22, 2026→Aug 31, 2027
    Study completion Sep 22, 2026→Aug 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01909245
Responsible party
Sponsor
First posted
Jul 26, 2013
Start date
Jul 10, 2015
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Fouad Kandeel, MD, PhD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunosuppressive Agents

Start the discussion